2012
DOI: 10.1245/s10434-012-2264-z
|View full text |Cite
|
Sign up to set email alerts
|

The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study

Abstract: CCRS followed by HIPEC with oxaliplatin for PC from CRC can be implemented with acceptable morbidity. Long-term DFS and OS can be achieved in selected patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
72
0

Year Published

2013
2013
2019
2019

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 93 publications
(75 citation statements)
references
References 42 publications
3
72
0
Order By: Relevance
“…In this context, intraperitoneal (IP) administration of chemotherapeutics has shown to be superior over the intravenous route [11,12], particularly due to the ability to maintain high concentrations of cytotoxic agents in the peritoneal cavity [13]. Also, promising data have resulted from clinical trials evaluating hyperthermic intraperitoneal chemoperfusion (HIPEC) immediately after cytoreductive surgery [14,15]. HIPEC involves flushing the peritoneal cavity with chemotherapeutic agents at an elevated temperature of 41-42°C.…”
Section: Introductionmentioning
confidence: 99%
“…In this context, intraperitoneal (IP) administration of chemotherapeutics has shown to be superior over the intravenous route [11,12], particularly due to the ability to maintain high concentrations of cytotoxic agents in the peritoneal cavity [13]. Also, promising data have resulted from clinical trials evaluating hyperthermic intraperitoneal chemoperfusion (HIPEC) immediately after cytoreductive surgery [14,15]. HIPEC involves flushing the peritoneal cavity with chemotherapeutic agents at an elevated temperature of 41-42°C.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, metastasis or recurrence occurs in a large number of patients following surgical resection, affecting the prognosis of the patients. Therefore, the five-year survival rate is low (64%), posing a serious threat to patient health (5,6).…”
Section: Introductionmentioning
confidence: 99%
“…The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal oxaliplatin (HIO) is a promising strategy for PC treatment (2) since retrospective and prospective analyses, including phase II and phase III clinical trials, as well as meta-analysis, have evidenced its survival benefit, relative to standard palliative surgery and/or chemotherapy (SPSC), in patients with resectable PC of colorectal origin (3,4). The efficacy of this innovative treatment has also been reported in phase II studies in ovarian cancer (5,6) and in phase III studies in gastric cancer (7,8).…”
Section: Introductionmentioning
confidence: 99%